• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Melt Pharmaceuticals, Inc.

    Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    Tickers HROW
    Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    Tickers HROW
    Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    Tickers HROW
    Melt Pharmaceuticals Provides Corporate Update
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    Tickers HROW
    Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    Tickers HROW
    Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    Tickers HROW
    Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    Tickers HROW
    Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    Tickers HROW
    Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    Tickers HROW
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.